In 2007 ISPE developed The “Certified Pharmaceutical Industry Professional” (CPIP) credential which was created to enhance the capabilities of the pharmaceutical professionals, organizations working in the industry, and the industry’s ability to provide life-saving drugs to society.
The CPIP was governed by the Professional Certification Commission (PCC), which was granted responsibility by the ISPE Board of Directors to provide oversight to the development and administration of the certification program.
In September of 2013, the ISPE Board of Directors made the decision to transition the CPIP program to a recertification program, closing the program to new applicants after November 30, 2013, permitting those already engaged in preparation to complete the certification by June 30, 2014, and permitted those who held the CPIP credential to retain the credential if they met the recertification requirements in effect at the time.
In November 2013, The ISPE board approved a revised Governance structure which inactivated the existing Professional Certification Commission (PCC) and created the Professional Re-certification Committee (PRCC) whose role is to administer a credible recertification program to further and promote the interests of industry and the public. The PRCC has the following responsibilities
Sam DeMarco, CPIP, President Compliance Team Inc, United States
"I believe that the credential has made me more confident and I feel that my clients engage me in more philosophical discussions on pharmaceutical industry subject matter. I get the sense that my clients 'listen' to me in a more serious 'in tune' way."
Marc Fleischman, CPIP, Facility and Verification Engineer, Genzyme, a Sanofi Company
"I chose to pursue the CPIP certification as a way to learn new phases of the industry and to codify my existing knowledge. As I prepared and studied for the exam, I was challenged to develop a broader understanding of many industry concepts that I had not been routinely exposed to. The experience has left me with a deep understanding of GMP regulation and broad industry knowledge across the entire bio/pharm lifecycle."